Form 4: EXAGEN Director Tina Susan Nova Acquires 13,500 Stock Options, Aligning Interests with Shareholders

EXAGEN Inc. Director Tina Susan Nova has acquired 13,500 stock options with an exercise price of $7.36, as reported in a recent SEC Form 4 filing, signaling continued alignment with the company's long-term performance.

Summary

• Tina Susan Nova, a Director of EXAGEN INC. (XGN), acquired 13,500 stock options.
• The transaction date for the acquisition was June 10, 2025.
• The exercise price for these stock options is $7.36 per share.
• The options are for Common Stock, with each option representing the right to buy one share.
• The options will expire on June 9, 2035.
• The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders.
• Vesting is subject to Ms. Nova's continued service on the board of directors of EXAGEN INC. through the vesting date.
• Following this transaction, Ms. Nova beneficially owns 13,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns the director's financial interests with the long-term success of the company and its shareholders. It is a routine compensation event, not indicative of extraordinary news, but reinforces governance alignment.

Positives

• The acquisition of stock options by a director aligns their personal financial interests with the long-term performance and shareholder value of EXAGEN INC.
• The grant of options serves as a form of incentive compensation, encouraging the director to contribute to the company's growth and success.

Future Outlook

The vesting schedule of the stock options, tied to continued service on the board, indicates an expectation of ongoing commitment from the director and aligns their incentives with the company's future performance and shareholder returns.

Management Comments

• The filing was signed by Jeffrey G. Black, as attorney-in-fact for Tina Susan Nova.

Industry Context

The granting of stock options to directors is a common and widely accepted practice across various industries, including the biotechnology and healthcare sectors where EXAGEN Inc. likely operates. This form of compensation is designed to align the interests of board members with those of the company's shareholders, promoting long-term value creation.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation mechanism used by publicly traded companies globally to incentivize long-term performance and align director interests with shareholder value. For example, companies like Amgen (AMGN) or Gilead Sciences (GILD) in the biotech sector frequently use equity-based compensation for their board members.
• The vesting conditions, typically tied to continued service or performance milestones, are also standard practice, ensuring that the incentive remains effective over time.

Related Party Transactions

• The acquisition of stock options by Tina Susan Nova, a Director of EXAGEN INC., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: Positive impact as the director's interests are further aligned with the company's long-term stock performance, potentially leading to better governance and strategic decisions.
• Employees: Indirectly positive, as strong leadership and aligned interests can contribute to overall company stability and growth.

Next Steps

• The stock options will become fully vested and exercisable on the first anniversary of the grant date (June 10, 2026) or the next annual meeting of the Issuer's stockholders, whichever occurs first, provided Tina Susan Nova continues her service on the board.

Key Dates

Recommendation

Keywords

EXAGEN, XGN, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Tina Susan Nova